suggested that the accumulation of intracellular iron contributes to chemotherapy resistance, and that iron efflux induced by transferrin could enhance doxorubicin sensitivity in estrogen receptor-positive (ER+) breast cancers (29). The gene discussed is ESR1; the disease is breast carcinoma.